X4 Pharmaceuticals Inc. (XFOR)
NASDAQ: XFORHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
XFOR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $306.34M
- P/E (TTM)
- 5.45
- EPS (TTM)
- $0.55
- Dividend yield
- None
- 52-week range
- 2.43 – 4.83
- Day range
- 2.89 – 3.06
- Volume / Avg
- 1.83M / 877.70K
- Beta
- —
- Shares outstanding
- 102.11M
52-week range
XFOR stock today
Shares of X4 Pharmaceuticals (XFOR) finished higher on Nov 20 at $3.00, a gain of 1.35% or $0.04 per share, versus the S&P 500's 3.70% decline. Volume was 2.1x the average at 1.83M shares, a sign of unusually heavy trading. Shares are 37.9% below their 52-week high of $4.83, set on Mar 10, 2026 and 23.5% above the 52-week low of $2.43, in the middle of the past year's range.
XFOR is down 25.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 20.0%. X4 Pharmaceuticals trades at 5.5x its trailing twelve-month earnings per share of $0.55.
Summary generated from market data by MetaCap's automated system. Methodology
About X4 Pharmaceuticals
Company profileX4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Headquarters
- Boston, MA
- Employees
- 45
- IPO year
- 2017
- Website
- x4pharma.com
Financial highlights
Full financialsIn fiscal 2025, X4 Pharmaceuticals generated $6.5 million in revenue, up 150.0% from fiscal 2024, its 2nd consecutive year of revenue growth. X4 Pharmaceuticals reported a net loss of $79.2 million, compared with a loss of $37.5 million a year earlier. Gross margin was 11.4% (down from 69.3%) and operating margin -1336.7%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $6.50M | $2.60M | $0 | $0 | $0 |
| Growth | +150.00% | — | — | — | -100.00% |
| Net income | $-79.20M | $-37.45M | $-101.17M | $-93.87M | $-88.70M |
| EPS (diluted) | $-1.87 | $-5.59 | $-17.07 | $-1.52 | $-3.99 |
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$11.60+286.67%
- Strong buy 0
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $-0.16 vs $-0.19
- Surprise
- +15.79%
XFOR news
All XFOR news- X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Tops Revenue EstimatesNasdaqXFOR, MRNA
- X4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire
- X4 Pharmaceuticals to Participate in Guggenheim, Stifel, and Jefferies Conferences in November 2026GlobeNewswire
- X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor DayGlobeNewswire
- X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion LeadersGlobeNewswire
- X4 Strengthens Cash Position Ahead Of Key Phase 3 MilestonesNasdaqXFOR, ET
X4 Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TRXBTRex Bio Inc. | 10.32 | +6.12% | $296.95M | vs XFOR |
| SLBTSL Science Holding Limited | 0.55 | -3.36% | $308.42M | vs XFOR |
| DTILPrecision BioSciences Inc. | 7.40 | +7.09% | $282.46M | vs XFOR |
| CCCCC4 Therapeutics Inc. | 2.48 | +1.64% | $325.67M | vs XFOR |
| AGENAgenus Inc. | 5.97 | -2.77% | $270.12M | vs XFOR |
| KYTXKyverna Therapeutics Inc. | 4.26 | -2.52% | $269.33M | vs XFOR |
| AGMBAgomAb Therapeutics NV ADR | 5.45 | -3.02% | $268.40M | vs XFOR |
| OCGNOcugen Inc. | 0.7679 | +4.79% | $260.55M | vs XFOR |
Indexes, lists and sector
X4 Pharmaceuticals stock FAQ
What is X4 Pharmaceuticals's stock price today?
XFOR last traded at $3.00 as of Nov 20, 4:00 PM EST, up 1.35% on the day. Prices are delayed at least 15 minutes.
Does X4 Pharmaceuticals pay a dividend?
No. X4 Pharmaceuticals does not currently pay a regular cash dividend.
What is XFOR's P/E ratio?
XFOR trades at a trailing P/E ratio of 5.45.
Has XFOR ever split its stock?
Yes. The most recent XFOR stock split was a 1-for-30 split on Apr 28, 2025, one of 2 splits on record.
What is the XFOR 52-week high?
The 52-week high for XFOR is $4.83 and the 52-week low is $2.43. The stock is currently 37.9% below its high.